Leucine-rich repeat serine/threonine-protein kinase 2

For Research Use Only. Not for use in diagnostic procedures.

Synthetic

LRRK2 siRNA (Mouse) is a target-specific 19-23 nt siRNA oligo duplexes designed to knock down gene expression.

> 97%

Lyophilized powder

Shipped at 4 degree C. Store at -20 degree C for one year.

siRNA Negative Control (Catalog# MBS8241404) is a non-targeting 21 nt siRNA recommended as a negative control for experiments using targeted siRNA transfection.

Small volumes of LRRK2 sirna vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

siRNA to inhibit LRRK2 expression using RNA interference

RNA Interference (RNAi)

284,732 Da

leucine-rich repeat kinase 2

leucine-rich repeat serine/threonine-protein kinase 2

Leucine-rich repeat serine/threonine-protein kinase 2

LRRK2_MOUSE

LRRK2: a large multidomain protein kinase with a TKL-type kinase domain, multiple protein-protein interaction domains and a mitochondrial Rho domain (MIRO). May play a role in the etiology of Parkinson disease. May also have GTPase activity. Positively regulates autophagy through a calcium-dependent activation of the CaMKK/AMPK signaling pathway. The process involves activation of nicotinic acid adenine dinucleotide phosphate (NAADP) receptors, increase in lysosomal pH, and calcium release from lysosomes. Interacts with PARK2, PRDX3 and TPCN2. Expressed throughout the ***** brain, but at a lower level than in heart and liver. Expressed in the cerebellum, cerebral cortex, medulla, spinal cord occipital pole, frontal lobe, temporal lobe and putamen. Expression is particularly high in brain dopaminoceptive areas. Defects in LRRK2 are the cause of Parkinson disease type 8 (PARK8). A slowly progressive neurodegenerative disorder characterized by bradykinesia, rigidity, resting tremor, postural instability, neuronal loss in the substantia nigra, and the presence of neurofibrillary MAPT (tau)-positive and Lewy bodies in some patients.

Protein type: Protein kinase, Ser/Thr (non-receptor); Protein kinase, TKL; EC 2.7.11.1; Kinase, protein; TKL group; LRRK family

Cellular Component: dendrite cytoplasm; Golgi apparatus; extracellular space; mitochondrion; lysosome; dendrite; terminal button; inclusion body; trans-Golgi network; ribonucleoprotein complex; cytosol; lipid raft; synaptic vesicle; mitochondrial outer membrane; membrane; cell soma; mitochondrial matrix; mitochondrial inner membrane; cytoplasm; synapse; cytoplasmic vesicle; intracellular; endosome; neuron projection; intracellular membrane-bound organelle; endoplasmic reticulum; perikaryon; cell projection; axon; mitochondrial membrane; plasma membrane; cell junction

Molecular Function: tubulin binding; GTPase activity; identical protein binding; GTP-dependent protein kinase activity; clathrin binding; protein homodimerization activity; Rho GTPase binding; GTP binding; nucleotide binding; actin binding; GTPase activator activity; protein kinase activity; transferase activity; MAP kinase kinase activity; protein serine/threonine kinase activity; protein binding; SNARE binding; transferase activity, transferring phosphorus-containing groups; protein kinase A binding; syntaxin-1 binding; kinase activity; glycoprotein binding; ATP binding

Biological Process: regulation of synaptic transmission, glutamatergic; activation of MAPKK activity; positive regulation of protein binding; activation of MAPK activity; protein amino acid autophosphorylation; regulation of neuron maturation; determination of ***** life span; protein amino acid phosphorylation; tangential migration from the subventricular zone to the olfactory bulb; negative regulation of protein amino acid phosphorylation; regulation of dopamine receptor signaling pathway; small GTPase mediated signal transduction; cell differentiation; regulation of mitochondrial depolarization; negative regulation of protein binding; Golgi organization and biogenesis; neuromuscular junction development; positive regulation of autophagy; positive regulation of dopamine receptor signaling pathway; olfactory bulb development; peptidyl-threonine phosphorylation; MAPKKK cascade; endocytosis; regulation of locomotion; regulation of membrane potential; positive regulation of programmed cell death; peptidyl-serine phosphorylation; positive regulation of protein ubiquitination; positive regulation of proteasomal ubiquitin-dependent protein catabolic process; intracellular distribution of mitochondria; autophagy; positive regulation of protein amino acid phosphorylation; response to oxidative stress; regulation of excitatory postsynaptic membrane potential; phosphorylation; neurite morphogenesis; positive regulation of GTPase activity

All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.

While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.

It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.